Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.

TEVA

Teva Pharmaceutical Indu... (TEVA)

Teva Pharmaceutical Industries Ltd
De:
Trier par:
 Showing the most relevant articles for your search:NYSE:TEVA
DateHeureSourceTitreSymboleSociété
06/12/202115h43Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NYSE:TEVATeva Pharmaceutical Industries Ltd
01/12/202114h00Business WireTeva Announces Launch of an Authorized Generic of Epiduo® Forte Gel (adapalene and benzoyl peroxide gel 0.3%/2.5%), in the U.S.NYSE:TEVATeva Pharmaceutical Industries Ltd
25/11/202118h00GlobeNewswire Inc.Quantum Genomics signs an exclusive license agreement with Teva Israel Ltd.NYSE:TEVATeva Pharmaceutical Industries Ltd
24/11/202113h51Edgar (US Regulatory)Current Report Filing (8-k)NYSE:TEVATeva Pharmaceutical Industries Ltd
10/11/202115h17Business WireTeva Announces Early Tender Results of its Debt Tender Offer, Increase of the Maximum Tender Amount and Election of Early SettlementNYSE:TEVATeva Pharmaceutical Industries Ltd
09/11/202111h56Business WireVon der Effektivität im Rahmen klinischer Versuchsreihen zur tatsächlichen Wirksamkeit - erste Daten zu AJOVY® ▼ (Fremanezumab) aus dem European Real World Evidence ProgrammNYSE:TEVATeva Pharmaceutical Industries Ltd
09/11/202111h54Business WireDe l'efficacité clinique à l'efficacité en monde réel : les premières données AJOVY® ▼ ▼ (frémanezumab) du programme European Real World EvidenceNYSE:TEVATeva Pharmaceutical Industries Ltd
08/11/202122h02Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NYSE:TEVATeva Pharmaceutical Industries Ltd
08/11/202110h25Business WireFrom Clinical Trial Efficacy to Real-World Effectiveness First AJOVY® ▼ (fremanezumab) Data from European Real World Evidence ProgramNYSE:TEVATeva Pharmaceutical Industries Ltd
04/11/202121h43Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NYSE:TEVATeva Pharmaceutical Industries Ltd
03/11/202111h00Business WireTeva Becomes First Pharmaceutical Company to Execute Sustainability-linked Bond Tied to both Climate and Access to Medicine TargetsNYSE:TEVATeva Pharmaceutical Industries Ltd
02/11/202122h31Business WireTeva Announces Successful Upsize of Sustainability-Linked Senior Notes Offering and Pricing of $5,000,000,000 of Sustainability-Linked Senior NotesNYSE:TEVATeva Pharmaceutical Industries Ltd
02/11/202122h30Edgar (US Regulatory)Free Writing Prospectus - Filing Under Securities Act Rules 163/433 (fwp)NYSE:TEVATeva Pharmaceutical Industries Ltd
02/11/202103h00Business WireCalifornia Judge Rules That Teva Did Not Cause a Public Nuisance or Make False or Misleading Statements About OpioidsNYSE:TEVATeva Pharmaceutical Industries Ltd
30/10/202122h00Business WireNew Phase 3 Data Presented at Psych Congress 2021 Showed TV-46000/mdc-IRM Significantly Prolonged Time to Impending Relapse Compared to Placebo in Patients with SchizophreniaNYSE:TEVATeva Pharmaceutical Industries Ltd
27/10/202114h52Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)NYSE:TEVATeva Pharmaceutical Industries Ltd
27/10/202113h15Business WireTeva Announces Launch of $4,000,000,000 Offering of Sustainability-linked Senior NotesNYSE:TEVATeva Pharmaceutical Industries Ltd
27/10/202113h15Business WireTeva Announces $3,500,000,000 Debt Tender Offers for Notes Due 2022-2024NYSE:TEVATeva Pharmaceutical Industries Ltd
27/10/202113h14Edgar (US Regulatory)Quarterly Report (10-q)NYSE:TEVATeva Pharmaceutical Industries Ltd
27/10/202113h00Business WireTeva Reports Third Quarter 2021 Financial ResultsNYSE:TEVATeva Pharmaceutical Industries Ltd
26/10/202122h45Business WireTeva and MODAG Announce Licensing Collaboration for Neurodegenerative Disease Drug CandidateNYSE:TEVATeva Pharmaceutical Industries Ltd
21/10/202114h00Business WireTeva to Present New Data from Growing Mental Health Portfolio at Psych Congress 2021NYSE:TEVATeva Pharmaceutical Industries Ltd
13/10/202119h53Business WireNouvelles données relatives à l'innocuité du traitement par COPAXONE® (acétate de glatiramère) chez des mères allaitantes atteintes de sclérose en plaques cycliqueNYSE:TEVATeva Pharmaceutical Industries Ltd
13/10/202117h33Business WireNeue Sicherheitsdaten zur Behandlung mit COPAXONE® (Glatirameracetat) von stillenden Müttern mit schubförmiger multipler SkleroseNYSE:TEVATeva Pharmaceutical Industries Ltd
13/10/202108h00Business WireNew Safety Data on treatment with COPAXONE® (glatiramer acetate) of Breastfeeding Mothers who Live with Relapsing Multiple SclerosisNYSE:TEVATeva Pharmaceutical Industries Ltd
04/10/202119h59Business WireLes distances parcourues par les médicaments deviennent une source d'inquiétude pour les patients européensNYSE:TEVATeva Pharmaceutical Industries Ltd
04/10/202116h54Business Wire„Medicine Miles“ werden zu einem Problem für europäische PatientenNYSE:TEVATeva Pharmaceutical Industries Ltd
04/10/202108h00Business Wire‘Medicine Miles’ Becoming a Concern for European PatientsNYSE:TEVATeva Pharmaceutical Industries Ltd
01/10/202116h20Business WireTeva to Host Conference Call to Discuss Third Quarter 2021 Financial Results at 8 a.m. ET on October 27, 2021NYSE:TEVATeva Pharmaceutical Industries Ltd
30/09/202114h00Business WireTeva to Present 8 Abstracts on AJOVY® (fremanezumab-vfrm) Injection and Hold Symposium on Healthcare Disparities at WCNNYSE:TEVATeva Pharmaceutical Industries Ltd
 Showing the most relevant articles for your search:NYSE:TEVA